Gold nanorod hybrid vesicles for near-infrared two-region photothermal therapy and preparation method of gold nanorod hybrid vesicles

Through the combined use of surface-functionalized self-assembled gold nanorod hybrid drug-loading vesicles with 17-AAG, the problem of heat stress in photothermal treatment is solved, the treatment efficiency is improved, and the utilization of near-infrared second-zone lasers is improved. efficiency.

CN118987207APending Publication Date: 2024-11-22EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411056533.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In photothermal therapy, high temperature induced heat stress causes tumor cells to develop heat resistance and reduce treatment efficiency. It is difficult for the prior art to effectively utilize the photothermal conversion efficiency of near-infrared two-zone lasers.

Method used

The surface-functional self-assembled gold nanorods are used to modify the upper critical dissolution temperature polymer and amphiphilic polymer to form a gold nanorod hybrid drug-loading vesicle with a longitudinal plasma absorption peak located in the near infrared region 2, combined with 17-AAG, as an HSP90 inhibitor, achieves photocontrolled drug release and combined chemotherapy.

Benefits of technology

It improves the efficiency of photothermal treatment, reduces the heat stress of tumor cells, enhances the therapeutic effect on solid tumors, and improves the application limitations of near-infrared second-zone lasers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976600880000061
    Figure BDA0004976600880000061
  • Figure BDA0004976600880000062
    Figure BDA0004976600880000062
  • Figure BDA0004976600880000071
    Figure BDA0004976600880000071
Patent Text Reader

Abstract

The invention provides a gold nanorod hybrid vesicle for near-infrared two-region photothermal therapy and a preparation method of the gold nanorod hybrid vesicle. Specifically, the invention provides a surface-functionalized self-assembled gold nanorod, the surface of the gold nanorod is modified with an upper critical solution temperature type polymer and an amphiphilic polymer, and the critical solution temperature of the upper critical solution temperature type polymer is 40-55 DEG C. The invention further provides the gold nanorod hybrid drug-loaded vesicle. The gold nanorod hybrid drug-loaded vesicle can be used for near-infrared two-region photothermal therapy, can effectively perform photothermal conversion under 1064nm laser irradiation, and responsively releases chemotherapeutic drugs, so that photothermal therapy and chemotherapy combined with solid tumors are realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of nano drug delivery, and specifically relates to a gold nanorod hybrid vesicle for near-infrared second-zone photothermal therapy and a preparation method thereof. Background Art

[0002] Photothermal therapy is an emerging treatment method that converts light energy into heat energy to locally heat tumor tissue and kill tumor cells. Compared with traditional tumor treatment methods (surgery, radiotherapy and chemotherapy), photothermal therapy has the characteristics of fewer side effects, less invasiveness (minimally invasive), low equipment cost and precise targeting.

[0003] Lasers with absorption wavelengths in the near-infrared region are the preferred light sources for photothermal therapy. In this band, the autofluorescence of organisms is weak, and light absorption and scattering are also less, which allows the laser to penetrate deeply into the tissue effectively while reducing light loss and avoiding heating of healthy tissue. Compared with near-infrared region I (NIR-I, 650-950nm) lasers, near-infrared region II (NIR-II, 1000-1700nm) lasers have significant advantages in tissue penetration and radiation safety, allowing for higher laser irradiation powers.

[0004] Gold nanorods are a class of inorganic nanomaterials with excellent photothermal conversion properties. On the one hand, gold nanorods have high chemical stability and are easy to modify; on the other hand, they have the characteristic of adjustable absorption wavelength. By adjusting the aspect ratio of gold nanorods, their longitudinal plasmon absorption peak can be red-shifted to the near-infrared region II. Gold nanorod vesicles are hollow bubble structures formed by self-assembly of functionally modified gold nanorods, showing excellent drug loading capacity. Depending on the type of modified polymer, gold nanorod vesicles can achieve stimulus-responsive drug release.

[0005] The high temperature generated by photothermal therapy can induce heat stress in tumor cells, leading to overexpression of heat shock proteins (HSP70, HSP90), making tumor cells heat-resistant and thus weakening the therapeutic effect. 17-(Allylamino)-17-demethylgeldanamycin (tanspiramycin, 17-AAG) is an HSP90 inhibitor with significantly lower hepatotoxicity than geldanamycin. The release of 17-AAG during photothermal therapy can reduce the expression of heat shock proteins (HSP), effectively reduce the thermal stress of tumor cells, improve the efficiency of treatment, and achieve synergistic effects. Summary of the invention

[0006] The purpose of the present invention is to provide a gold nanorod hybrid vesicle for near-infrared second-zone photothermal therapy and a preparation method and application thereof.

[0007] The first aspect of the present invention provides a surface functionalized self-assembling gold nanorod, wherein the surface of the gold nanorod is modified with an upper critical solution temperature polymer and an amphiphilic polymer, wherein the critical solution temperature of the upper critical solution temperature polymer is 40-55°C.

[0008] The second aspect of the present invention provides a gold nanorod vesicle, wherein the gold nanorod vesicle is self-assembled from the surface-functionalized self-assembling gold nanorods described in the first aspect of the present invention.

[0009] The third aspect of the present invention provides a gold nanorod hybrid drug-loaded vesicle, which comprises the gold nanorod hybrid drug-loaded vesicle according to the second aspect of the present invention, and a drug in the inner cavity of the gold nanorod vesicle.

[0010] In one or more embodiments, the drug is an HSP90 inhibitor; preferably, the drug is tanespiramycin; preferably, the diameter of the gold nanorod hybrid drug-loaded vesicles is 145-155 nm.

[0011] The fourth aspect of the present invention provides a method for preparing the gold nanorod hybrid drug-loaded vesicles described in the third aspect of the present invention, the method comprising adding HEPES buffer to the solution of the surface functionalized self-assembled gold nanorods described in the first aspect of the present invention, stirring, then adding a solution containing the drug, stirring, and evaporating the solvent to obtain the gold nanorod hybrid drug-loaded vesicles, wherein the solvent is preferably tetrahydrofuran.

[0012] The fifth aspect of the present invention provides a pharmaceutical composition, which comprises the gold nanorod hybrid drug-loaded vesicles described in the third aspect of the present invention and a pharmaceutically acceptable carrier.

[0013] The sixth aspect of the present invention provides a use of the gold nanorod hybrid drug-loaded vesicles described in the third aspect of the present invention in the preparation of a drug for treating tumors; preferably, the drug is used in combination with photothermal therapy.

[0014] The seventh aspect of the present invention provides an application of the gold nanorods of the present invention, the surface-functionalized self-assembled gold nanorods described in the first aspect of the present invention, the amphiphilic polymer of the present invention and the upper critical solution temperature polymer of the present invention in the preparation of the gold nanorod hybrid drug-loaded vesicles described in the third aspect of the present invention.

[0015] In an eighth aspect of the present invention, there is provided a method for light-controlled drug release of the gold nanorod hybrid drug-loaded vesicles according to the third aspect of the present invention, the method comprising irradiating the gold nanorod hybrid drug-loaded vesicles with a laser having a wavelength of 1060-1070 nm, wherein the power density of the laser is preferably 0.5-1.5 W / cm 2 . BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 These are the transmission electron microscopy (TEM) images of SGNRs, USGRVs and USGRV-17-AAG in Example 1, wherein a is the TEM of SGNRs, b is the TEM of SGNRs, and c is the TEM of USGRV-17-AAG.

[0017] Figure 2 Absorption spectra of SGNRs, USGNRs and USGRVs in Example 1.

[0018] Figure 3 Zeta potential diagram of SGNRs, USGRVs and USGRV-17-AAG in Example 1 (a) and hydration kinetic particle size distribution diagram of USGRVs and USGRV-17-AAG (b).

[0019] Figure 4 Turbidity curve (a) and infrared spectrum (b) of upper critical solution temperature (UCST) polymer (P(AAm-co-AN)).

[0020] Figure 5 The drug release curves of USGRV-17-AAG in Example 1 at different temperatures.

[0021] Figure 6 The photothermal heating curves of USGRV-17-AAG in Example 1 at different laser powers (a) or different concentrations (b).

[0022] Figure 7 The photothermal stability curve (a) and thermal imaging image (b) of USGRV-17-AAG in Example 1.

[0023] Figure 8 The continuous light-controlled release curve (a) and the intermittent light-controlled release curve (b) of USGRV-17-AAG in Example 1 are shown.

[0024] Fig. 9 Figure 2 is a cytotoxicity test diagram of USGRV-17-AAG. Cell viability of MDA-MB-231 cells incubated with different concentrations of nanoparticles USGRVs and USGRV-17-AAG under laser irradiation and without laser irradiation.

[0025] Fig.10 Live / dead cell staining of USGRV-17-AAG. Live / dead cell staining results of MDA-MB-231 cells incubated with PBS, 17-AAG, USGRVs and USGRV-17-AAG under laser irradiation or without laser irradiation.

[0026] Fig.11 Figure 2 shows the tumor inhibition of USGRV-17-AAG. (a) Schematic diagram of the experimental design. (b) Tumor volume growth curve and (c) tumor growth inhibition rate of MDA-MB-231 tumor-bearing mice after treatment with different nanoformulations, and (d) TUNEL and H&E staining of mouse tumor tissue sections. DETAILED DESCRIPTION

[0027] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.

[0028] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.

[0029] Herein, “comprising”, “including”, “containing” and similar terms encompass the meanings of “consisting essentially of” and “consisting of”. For example, when “A comprises B and C” is disclosed herein, “A consists essentially of B and C” and “A consists of B and C” should be deemed to be disclosed herein.

[0030] In this article, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are only for brevity and convenience. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values ​​within the range (including integers and fractions).

[0031] In this document, unless otherwise specified, percentage refers to mass percentage and ratio refers to mass ratio.

[0032] Herein, when describing embodiments or examples, it should be understood that they are not used to limit the present invention to these embodiments or examples. On the contrary, all substitutes, improvements and equivalents of the methods and materials described in the present invention can be included in the scope limited by the claims.

[0033] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.

[0034] Herein, the “aspect ratio of the gold nanorod” refers to the ratio of the longitudinal length to the cross-sectional width of the prepared gold nanorod.

[0035] In this article, "longitudinal plasmon absorption peak" refers to the longitudinal local surface plasmon resonance peak (l-LSPR peak) of gold nanorods. By controlling the aspect ratio of gold nanorods, the l-LSPR peak can be located in the near-infrared region II to achieve near-infrared light-excited photothermal therapy.

[0036] As used herein, "pharmaceutical composition" refers to a preparation of the gold nanorod hybrid drug-loaded vesicles of the present invention and a medium generally accepted in the art for delivering the bioactive gold nanorod hybrid drug-loaded vesicles to mammals (e.g., humans). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to promote administration of the organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0037] As used herein, "pharmaceutically acceptable" refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the gold nanorod hybrid drug-loaded vesicles of the present invention and is relatively non-toxic, that is, the substance can be administered to an individual without causing adverse biological reactions or interacting in an adverse manner with any components contained in the composition.

[0038] As used herein, "effective amount" refers to the amount of a therapeutic agent that treats, alleviates or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or preventive effect. The precise effective amount for a subject depends on the subject's size and health, the nature and extent of the condition, and the therapeutic agent and / or combination of therapeutic agents selected for administration. Therefore, it is not useful to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experimentation, which is within the judgment of the clinician.

[0039] As used herein, "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or livestock use.

[0040] The purpose of the present invention is to provide a temperature-responsive gold nanorod hybrid drug-loaded vesicle with a longitudinal plasma absorption peak located in the second near-infrared region, in order to address the problems of poor efficacy and large side effects of traditional tumor treatments, and to provide a method for preparing the new nanoparticles.

[0041] Specifically, the present invention provides a gold nanorod hybrid drug-loaded vesicle that can be used for near-infrared second-zone laser (1064nm) light-controlled drug release and photothermal therapy, wherein the nano drug-loaded vesicle comprises gold nanorods that can achieve efficient photothermal conversion and a temperature-responsive polymer P(AAm-co-AN), as well as an amphiphilic polymer PEG 45 -b-PS 450 As a self-assembly unit, it is loaded with the chemotherapy drug 17-AAG to achieve combined treatment. The chemotherapy drug 17-AAG is an inhibitor of heat shock protein, which can reduce the heat resistance of tumors during hyperthermia treatment and achieve combined treatment.

[0042] The longitudinal plasma absorption peak of the gold nanorod of the present invention is located in the near-infrared region II, and can be excited by the laser in the near-infrared region II to achieve photothermal therapy. Therefore, the present invention provides a gold nanorod that can be used for photothermal therapy in the near-infrared region II. The longitudinal length of the gold nanorod of the present invention is 65-70nm, for example, 66-69nm, 67-68nm. The cross-sectional width of the gold nanorod of the present invention is 8-9nm, for example, 8.5-8.9nm. The aspect ratio of the gold nanorod of the present invention is 7-8, for example, 7.5-7.7. The longitudinal plasma absorption peak of the gold nanorod of the present invention is located at 1000-1700nm, preferably at 1050-1150nm, and more preferably at 1070-1100nm or 1080-1090nm, for example, 1083nm. In some embodiments, the gold nanorods have a longitudinal length of 67.48±6.14 nm, a cross-sectional width of 8.82±1.15 nm, an aspect ratio of 7.65, and a longitudinal plasmon absorption peak at 1083 nm.

[0043] The surface-functionalized self-assembled gold nanorods of the present invention can be self-assembled into gold nanorod vesicles, and the self-assembled gold nanorod vesicles can achieve temperature response. Therefore, the present invention provides a surface-functionalized self-assembled gold nanorod. The surface-functionalized self-assembled gold nanorods of the present invention include the gold nanorods of the present invention, and the surface of the gold nanorods of the present invention is modified with an upper critical solution temperature type polymer and an amphiphilic polymer. The longitudinal plasma absorption peak of the surface-functionalized self-assembled gold nanorods of the present invention is located at 1000-1020nm, for example, 1010nm. The critical solution temperature of the upper critical solution temperature type polymer of the present invention is 40-55°C, preferably 43-53°C, for example, 43°C.

[0044] In one or more embodiments, the present invention provides an amphiphilic polymer having a structure shown in Formula I:

[0045]

[0046] In Formula I, s is an integer between 40-50, and t is an integer between 440-460.

[0047] In some embodiments, s is an integer between 43-47.

[0048] In some embodiments, t is an integer between 445-455.

[0049] In some embodiments, the amphiphilic polymer has the structure shown in the following formula:

[0050]

[0051] The amphiphilic polymer can be represented by PEG 45 -b-PS 450 The polymerization degrees of PEG and PS are 45 and 450, respectively.

[0052] In one or more embodiments, the present invention provides an upper critical solution temperature polymer, represented by P(AAm-co-AN), which has the structure shown in the following formula II:

[0053]

[0054] wherein m is an integer selected from 200-240, and n is an integer selected from 10-30.

[0055] In formula II, m represents the degree of polymerization of acrylamide (AAm), and n represents the degree of polymerization of acrylonitrile (AN). By adjusting the degree of polymerization of AAm and the degree of polymerization of AN in the compound of formula II (i.e., adjusting the values ​​of m and n), the critical solution temperature of the upper critical solution temperature type polymer can be regulated. In some embodiments, m is an integer selected from 210-230, and m is preferably an integer selected from 215-225, such as 216, 217, 218, 219, 220, 221, 222, 223, 224. In some embodiments, n is an integer selected from 15-25, such as 16, 17, 18, 19, 20, 21, 22, 23, 24. In some embodiments, m is 220 and n is 20. In some embodiments, the critical solution temperature of the upper critical solution temperature type polymer is 43°C.

[0056] The present invention also provides a gold nanorod vesicle self-assembled from the surface functionalized self-assembling gold nanorods of the present invention. In some embodiments, the diameter of the gold nanorod vesicle is 180-185nm, such as 181-184nm. In some embodiments, the longitudinal plasma absorption peak of the gold nanorod vesicle is located at 1100-1200nm, such as 1150-1160nm.

[0057] The present invention also provides a gold nanorod hybrid drug-loaded vesicle, which comprises the gold nanorod vesicle of the present invention and a drug in the inner cavity of the gold nanorod vesicle. In some embodiments, the drug is an HSP90 inhibitor. Preferably, the drug is tansspiramycin (17-AAG). In some embodiments, the diameter of the gold nanorod hybrid drug-loaded vesicle is 145-155nm, for example 148-152nm.

[0058] The present invention provides a method for preparing the gold nanorods of the present invention, the method comprising the steps of: (a) quickly adding an ice-cold sodium borohydride aqueous solution into a growth solution containing hexadecyltrimethylammonium bromide, tetrachloroauric acid, silver nitrate, hydrochloric acid and hydroquinone, mixing evenly and growing the gold nanorods.

[0059] In some embodiments, the temperature of the ice-cold sodium borohydride aqueous solution may be 0-5°C, preferably 0°C. The concentration of the sodium borohydride aqueous solution may be 5-15mM, for example 10mM. The growth may be carried out at 20-40°C, preferably at 25-35°C. The growth is carried out for 10-25 hours, preferably 15-20 hours. The molar ratio of tetrachloroauric acid to hexadecyltrimethylammonium bromide, silver nitrate, hydrochloric acid and hydroquinone is (1.5-1.7): (350-450): (1.5-2.5): (7-9): (20-22), for example 1.6: 400: 1: 8: 21. In some embodiments, hydroquinone is a reducing agent. In some embodiments, the method is a seedless method for preparing gold nanorods. In some embodiments, a gold nanorod colloidal solution is obtained after growing at 30°C for 16 hours. In some embodiments, the gold nanorod colloidal solution is centrifuged, washed and centrifuged, and separated and purified to obtain the gold nanorods.

[0060] In some embodiments, step (a) is: dissolving hexadecyltrimethylammonium bromide in water, adding tetrachloroauric acid aqueous solution, and then sequentially adding silver nitrate, hydrochloric acid and hydroquinone aqueous solution. After stirring until the solution is colorless, quickly adding freshly prepared sodium borohydride solution, standing and growing at 30°C for 16 hours, to obtain a gold nanorod colloidal solution.

[0061] The present invention provides a method for preparing an amphiphilic polymer (PEG 45 -b-PS 450 ), the method comprising the steps of (b): (b1) adding styrene, a macromolecular chain transfer agent PEG 45 -CTA and azobisisobutyronitrile are dissolved in 1,4-dioxane and oxygen is removed. The reaction is carried out at 60-100°C to obtain a pink precipitate PEG. 45 -b-PS 450 -CTA; (b2) PEG 45-b-PS 450 -CTA is dissolved in tetrahydrofuran, and n-butylamine is added to react under argon protection to obtain white powder PEG 45 -b-PS 450 .

[0062]

[0063] In some embodiments, the reaction of step (b1) can be carried out for 12-48 hours, preferably for 20-30 hours. In some embodiments, the reaction of step (b2) can be carried out for 10-60 minutes, preferably for 20-40 minutes. Preferably, in step b1, argon is used to remove oxygen, and the argon deoxygenation time is preferably 25-30 minutes. In some embodiments, PEG 45 -b-PS 450 -CTA is obtained by methanol precipitation. In some embodiments, PEG 45 -b-PS 450 Preferably, the PEG obtained is 45 -b-PS 450 -CTA and / or PEG 45 -b-PS 450 Repeat wash two, three, or four times.

[0064] In some embodiments, step (b) comprises: adding styrene, a macromolecular chain transfer agent PEG 45 -CTA and azobisisobutyronitrile were dissolved in 1,4-dioxane and argon was passed for 30 minutes to remove oxygen; after 30 minutes, the reaction bottle was placed in an oil bath at 80°C for 24 hours; after the reaction, the polymer precipitate was washed with methanol three times and vacuum dried to obtain a pink precipitate PEG 45 -b-PS 450 -CTA; PEG 45 -b-PS 450 -CTA was dissolved in tetrahydrofuran, and n-butylamine was added to react for 30 minutes under argon protection; then, the polymer was precipitated with methanol, and the polymer precipitate was dissolved with dimethyl sulfoxide; the polymer was washed three times according to the above washing steps, and a white powder PEG was obtained after drying under vacuum. 45 -b-PS 450 .

[0065] The present invention provides a method for preparing an upper critical solution temperature (UCST) type polymer (P(AAm-co-AN)), the method comprising the steps (c): (c1) dissolving acrylamide, azobisisobutyronitrile and 4-cyano-4-(thiobenzoyl)valeric acid in dimethyl sulfoxide and removing oxygen, then adding acrylonitrile, reacting the solution at 60-80°C, and after the reaction, using methanol to precipitate a polymer product c1; (c2) dissolving the polymer product c1 in dimethyl sulfoxide and removing oxygen, adding n-butylamine to react, obtaining a polymer product c2, dissolving the polymer product c2 in DMSO, dialyzing in ultrapure water and freeze-drying to obtain a UCST type thermosensitive polymer P(AAm-co-AN).

[0066]

[0067] In some embodiments, in step (c1), the amount of acrylamide is 1.9-2.1 g, and the amount of acrylonitrile is 700-750 mg, for example, the amount of acrylamide is 2.0 g, and the amount of acrylonitrile is 720 mg. In step (c1), the reaction is carried out for 12-48 hours, preferably for 20-30 hours. Preferably, acrylonitrile is added to the reaction system using a syringe. In step (c1), the polymer product c1 precipitated in methanol is dissolved using dimethyl sulfoxide to wash the polymer product c1. In step (c1), the polymer product c1 can be washed two, three or four times.

[0068] In step (c2), the reaction can be carried out for 5-20 minutes, preferably for 10-15 minutes. Before the polymer product c2 is dialyzed, the polymer product c2 is washed. Washing can be carried out two, three or four times. Washing can be carried out by dissolving the polymer product c2 precipitated in methanol in DMSO. Dialysis can be carried out for 1-5 days, preferably for 2-3 days. In some embodiments, the dialysis bag cutoff is 3.4-3.6kDa, for example 3.5kDa. In some embodiments, the UCST-type thermosensitive polymer P(AAm-co-AN) is a light yellow solid.

[0069] In step (c1) or step (c2), oxygen is removed by passing argon into the reaction system. The deoxygenation by passing argon can be carried out for 1-30 minutes, preferably for 5-20 minutes.

[0070] The present invention also provides a method for preparing surface functionalized self-assembled gold nanorods, the method comprising step (d): mixing the UCST type polymer P(AAm-co-AN) of the present invention and the amphiphilic polymer PEG 45 -b-PS 450The gold nanorod solution prepared in step (a) is dissolved in N,N-dimethylformamide, and is added dropwise under ultrasonic conditions; after ultrasonication, the mixture is stirred, centrifuged, and washed and centrifuged to obtain surface functionalized self-assembled gold nanorods (USGNRs).

[0071] In step (d), the UCST polymer P(AAm-co-AN) and the amphiphilic polymer PEG 45 -b-PS 450 The mass ratio may be 1:1. Ultrasound may be performed for 0.5-3 hours, preferably for 1-2 hours. The stirring is performed at 15-30°C, preferably at 20-25°C. Stirring may be performed for 12-48 hours, preferably for 20-30 hours. The centrifugation may be performed for 20-60 minutes, for example 30-50 minutes. The washing centrifugation may be performed using N,N-dimethylformamide. The washing centrifugation may be performed two, three or four times. The washing centrifugation is used to remove unmodified UCST-type polymer P(AAm-co-AN) and amphiphilic polymer PEG 45 -b-PS 450 In some embodiments, the prepared USGNRs are dispersed in THF for storage. The concentration of USGNRs stored in THF may be 0.5-1.5 mg / mL, for example 1 mg / mL. The USGNRs may be stored at 2-6°C, preferably 3-4°C.

[0072] The present invention also provides a method for preparing gold nanorod vesicles, which comprises step (e): adding HEPES buffer dropwise into the USGNRs solution, and after the addition is completed, completely evaporating tetrahydrofuran by stirring to obtain gold nanorod vesicles (USGRVs).

[0073] In step (e), the USGNRs solution is a tetrahydrofuran solution of USGNRs. The concentration of USGNRs in the USGNRs solution may be 0.5-1.5 mg / mL, for example 1 mg / mL. In some embodiments, the concentration of the HEPES buffer may be 0.3-0.5 mM, for example 0.4 mM. The volume ratio of the HEPES buffer to the USGNRs solution is (1.5-2.5): 1, for example 2: 1. The stirring is carried out at 20-30°C, for example 25°C, and the tetrahydrofuran is evaporated by stirring for 20-30 hours in an open state. In some embodiments, the reaction solution is stirred at room temperature (20-30°C, for example 25°C) for 24 hours to completely evaporate the tetrahydrofuran. In some embodiments, the obtained USGRVs are separated by centrifugation. In some embodiments, the obtained USGRVs are dispersed in ultrapure water and stored at 2-8°C, for example, at 4-6°C.

[0074] The present invention also provides a method for preparing gold nanorod hybrid drug-loaded vesicles, which comprises step (f): adding HEPES buffer dropwise into a USGNRs solution, performing a first stirring after the dropwise addition is completed, adding a tetrahydrofuran solution of 17-AAG, performing a second stirring, and obtaining gold nanorod hybrid drug-loaded vesicles (USGRV-17-AAG) after completely evaporating the tetrahydrofuran.

[0075] In step (f), the USGNRs solution is a tetrahydrofuran solution of USGNRs. The concentration of USGNRs in the USGNRs solution may be 0.5-1.5 mg / mL, for example 1 mg / mL. In some embodiments, the concentration of the HEPES buffer may be 0.3-0.5 mM, for example 0.4 mM. The volume ratio of the HEPES buffer to the USGNRs solution is (1.5-2.5): 1, for example 2: 1. The first stirring is carried out at 50-60°C. The first stirring is carried out for 5-20 min, for example 10-15 min. The second stirring is carried out at 50-60°C. The second stirring is carried out for 5-20 min, for example 10-15 min. After the reaction solution is cooled to room temperature (20-30°C, for example 25°C), it is stirred open for 20-30 hours to evaporate the tetrahydrofuran. In some embodiments, the reaction solution is cooled to room temperature (20-30°C, for example, 25°C) and stirred for 24 hours to completely evaporate tetrahydrofuran. In some embodiments, the prepared USGRV-17-AAG is separated by centrifugation and washed with water until there is no 17-AAG in the supernatant. In some embodiments, the prepared USGRV-17-AAG is dispersed in water for storage. In some embodiments, the prepared USGRV-17-AAG is dispersed in ultrapure water and stored at 2-8°C, for example, at 4-6°C.

[0076] In some embodiments, the gold nanorod hybrid drug-loaded vesicles of the present invention are composed of gold nanorods with longitudinal plasmon absorption peaks located in the second near-infrared region, amphiphilic polymers (PEG) modified on the surface of the gold nanorods, 45 -b-PS 450 ) and upper critical solution temperature (UCST) type polymer (P(AAm-co-AN)) and the chemotherapy drug tanspiramycin (17-AAG) encapsulated in gold nanorod vesicles.

[0077] Gold nanorods have high photothermal conversion efficiency and adjustable longitudinal plasma absorption peaks, and can be used for near-infrared second-zone photothermal therapy. Therefore, the present invention also provides the use of the gold nanorods of the present invention in tumor photothermal therapy and the preparation of gold nanorod hybrid drug-loaded vesicles. Gold nanorods, gold nanorod hybrid drug-loaded vesicles and preparation methods thereof are as described in any embodiment of the present invention.

[0078] The surface is covered with amphiphilic polymers (PEG45 -b-PS 450 ) modification can make gold nanorods have self-assembly properties, and the surface is modified with amphiphilic polymers (PEG 45 -b-PS 450 ) can be self-assembled into vesicles, therefore, the present invention also provides an amphiphilic polymer (PEG 45 -b-PS 450 ) in the self-assembly of gold nanorods into vesicles, and the vesicles are preferably used in tumor photothermal therapy. The amphiphilic polymer of the present invention can be used in the preparation of the surface functionalized self-assembled gold nanorods and gold nanorod hybrid drug-loaded vesicles of the present invention. The present invention also provides an amphiphilic polymer (PEG 45 -b-PS 450 ) in tumor photothermal therapy. 45 -b-PS 450 ) and its preparation method as described in any embodiment of the present invention.

[0079] UCST-type polymers (P(AAm-co-AN)) have a maximum critical solution temperature, and vesicles containing UCST-type polymers (P(AAm-co-AN)) can achieve temperature-controlled drug release. Therefore, the present invention provides the use of UCST-type polymers (P(AAm-co-AN)) in vesicle temperature-controlled drug release. The UCST-type polymers of the present invention can be used to prepare the surface-functionalized self-assembled gold nanorods and gold nanorod hybrid drug-loaded vesicles of the present invention. UCST-type polymers (P(AAm-co-AN)) and their preparation are as described in any embodiment of the present invention. In some embodiments, the vesicles may be gold nanorod drug-loaded vesicles of the present application.

[0080] UCST-type polymers (P(AAm-co-AN)) have the highest critical solution temperature, and gold nanorod hybrid drug-loaded vesicles have a high photothermal conversion efficiency. Therefore, gold nanorod hybrid drug-loaded vesicles containing UCST-type polymers (P(AAm-co-AN)) can achieve light-controlled drug release. The present invention provides the use of UCST-type polymers (P(AAm-co-AN)) in the preparation of gold nanorod hybrid drug-loaded vesicles and in tumor photothermal therapy. Gold nanorod hybrid drug-loaded vesicles and methods for preparing the same are as described in any embodiment of the present invention.

[0081] The surface is modified with the upper critical solution temperature polymer (P(AAm-co-AN)) of the present invention and the amphiphilic polymer (PEG 45 -b-PS 450) can be self-assembled into gold nanorod hybrid drug-loaded vesicles capable of light-controlled drug release. Therefore, the present invention also provides the use of surface-functionalized self-assembled gold nanorods in the preparation of gold nanorod hybrid drug-loaded vesicles. The surface-functionalized self-assembled gold nanorods, gold nanorod hybrid drug-loaded vesicles and their preparation methods are as described in any embodiment of the present invention.

[0082] HSP90 inhibitors (such as 17-AAG) can inhibit the overexpression of heat shock protein HSP90 during hyperthermia and play a chemotherapeutic role. The present invention combines HSP90 inhibitors with gold nanorod vesicles for photothermal therapy, and the prepared USGRV-17-AAG can significantly improve the treatment efficiency of tumors. Therefore, the present invention also provides the use of USGRV-17-AAG in tumor photothermal therapy.

[0083] The USGRV-17-AAG of the present invention can effectively perform photothermal conversion under 1060-1070nm (e.g., 1064nm) laser irradiation, and responsively release chemotherapeutic drugs to achieve photothermal therapy combined with chemotherapy for solid tumors. Therefore, the present invention also provides the use of USGRV-17-AAG in the preparation of a drug for treating tumors. In some embodiments, the drug is used in combination with photothermal therapy.

[0084] The present invention also provides a pharmaceutical composition, comprising the gold nanorod hybrid drug-loaded vesicle of the present invention and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition further comprises other anti-tumor drugs. In some embodiments, the pharmaceutical composition is combined with photothermal therapy.

[0085] The present invention also provides a method for treating tumors, the method comprising administering a therapeutically effective amount of gold nanorod hybrid drug-loaded vesicles or the pharmaceutical composition of the present invention to an individual in need, and irradiating the tumor site with laser after 20-30 hours. In some embodiments, the wavelength of the laser is 1060-1070nm, for example 1064nm. The power density of the laser can be 0.5-1.5W / cm 2 , for example 1W / cm 2 The laser spot area is 0.5-1.5cm 2 , for example 1cm 2 . The distance between the laser and the tumor site is 4-6 cm, for example, 5 cm. The laser is used to irradiate the tumor site for 4-6 minutes, for example, 5 minutes. The gold nanorod hybrid drug-loaded vesicles can be a solution of gold nanorod hybrid drug-loaded vesicles, for example, a gold nanorod hybrid drug-loaded vesicle aqueous solution. In some embodiments, the concentration of the gold nanorod hybrid drug-loaded vesicle solution is 40-60 μg / mL, for example, 50 μg / mL.

[0086] Compared with the prior art, the present invention has the following advantages:

[0087] The present invention modifies the gold nanorods that can realize photothermal conversion in the second near-infrared zone, so that it can realize self-assembly and have temperature responsive performance. The constructed nano drug-loaded vesicles can realize photothermal conversion and light-controlled drug release under 1064nm laser irradiation, further enriching the drug delivery system based on inorganic gold nanomaterials, and improving the current limitations of the application of near-infrared laser in the second near-infrared zone in the field of tumor photothermal therapy. The present invention further loads the chemotherapy drug 17-AAG, and by inhibiting the overexpressed heat shock protein during photothermal therapy, it avoids the generation of heat stress in tumor cells to a certain extent, thereby improving the treatment efficiency and achieving the purpose of combined treatment.

[0088] The present invention relates to the preparation and application of a gold nanorod hybrid drug-loaded vesicle that can be used for near-infrared second-zone photothermal therapy combined with chemotherapy. The gold nanorod of the present invention has a high photothermal conversion efficiency and an adjustable longitudinal plasma absorption peak, and can be used for near-infrared second-zone photothermal therapy. The amphiphilic polymer (PEG 45 -b-PS 450 ) enables the gold nanorods to have self-assembly properties, UCST-type polymers (P(AAm-co-AN)) enable nanovesicles to achieve light-controlled / temperature-controlled drug release, and 17-AAG can inhibit the overexpression of heat shock protein HSP90 during hyperthermia and play a chemotherapeutic role. USGRV-17-AAG can effectively perform photothermal conversion under 1064nm laser irradiation and responsively release chemotherapeutic drugs, realizing photothermal therapy combined with chemotherapy for solid tumors.

[0089] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0090] Herein, room temperature refers to 20-30°C, for example 25°C.

[0091] Example 1

[0092] A method for preparing gold nanorod hybrid drug-loaded vesicles that can be used for near-infrared second-zone photothermal therapy, the specific steps of which are as follows:

[0093] a. Preparation of gold nanorods with longitudinal plasma absorption peaks in the second near-infrared region: The preparation of gold nanorods (SGNRs) adopts a seedless method based on hydroquinone reduction. 100mL 0.1M CTAB (hexadecyltrimethylammonium bromide) aqueous solution and 1.39mL HAuCl4 aqueous solution (1% wt) were fully mixed at 30°C. Then 250μL 0.1M AgNO3 aqueous solution, 200μL 1M HCl aqueous solution and 5.25mL 0.1M hydroquinone aqueous solution were added in sequence. After stirring until the above mixed solution was colorless, 250μL 10mM freshly prepared ice-cold NaBH4 aqueous solution was quickly added. After thorough mixing, the solution was allowed to stand for 16 hours in a 30°C water bath. Then, the gold nanorods were purified and separated by centrifugation at a speed of 14000r / min for 40 minutes, and washed twice with ultrapure water to obtain SGNRs. The purified gold nanorods were dispersed and stored in ultrapure water, and the concentration of CTAB in the storage solution was about 1 mM.

[0094] b. Preparation of macromolecular chain transfer agent (PEG 45 -CTA): 2.5 g of methoxypolyethylene glycol (Mw: 2000), 0.523 g of 4-cyano-4-(thiobenzoyl)pentanoic acid, 386.86 mg of dicyclohexylcarbodiimide (DCC) and 229 mg of 4-dimethylaminopyridine (DMAP) were dissolved in 100 mL of anhydrous dichloromethane and stirred at 0°C for 40 hours. After the reaction was completed, the product was precipitated with icy ether and washed 3 times. After vacuum drying, a pink solid powder was obtained.

[0095] c. Preparation of amphiphilic polymers (PEG 45 -b-PS 450 ): 5.2g styrene, 200mg macromolecular chain transfer agent (PEG 45 -CTA) and 8.2 mg of azobisisobutyronitrile (AIBN) were dissolved in 6 mL of 1,4-dioxane, and argon was introduced to remove oxygen in the reaction system. After 30 minutes, the reaction bottle was placed in an 80°C oil bath for reaction for 24 hours. After 24 hours, the reaction was quenched in an ice-salt bath. The reaction solution was added dropwise to 60 mL of methanol to precipitate the polymer. After centrifugation (8500 rpm, 10 minutes), the precipitate was dissolved in 5 mL of tetrahydrofuran. The polymer was washed three times according to the above steps and vacuum dried to obtain a pink powder PEG 45 -b-PS 450 -CTA.

[0096] The obtained pink powder was dissolved in 5 mL of tetrahydrofuran, 493 μL of n-butylamine was added, and the reaction was carried out under argon protection for 30 minutes. Then, the polymer was precipitated with methanol, and the precipitate was dissolved with DMSO. The polymer was washed 3 times according to the above washing steps, and a white powder PEG was obtained after vacuum drying. 45-b-PS 450 . 1 H NMR (400MHz, CDCl3): δ7.02–6.39(m,2185H), 3.58(s,180H), 1.82–1.36(m,1413H).

[0097] d. Preparation of upper critical solution temperature (UCST) type polymer (P(AAm-co-AN)): 2.0 g acrylamide (AAm), 2.4 mg azobisisobutyronitrile (AIBN) and 20.4 mg 4-cyano-4-(thiobenzoyl)valeric acid (CPPA) were dissolved in 5 mL dimethyl sulfoxide (DMSO). Argon was introduced into the reaction system for 20 minutes to deoxygenate, and then 720 mg acrylonitrile (AN) was added using a syringe. After continuing to deoxygenate with argon for 5 minutes, the reaction bottle was placed in a 70°C oil bath for reaction. After 24 hours, the reaction bottle was placed in an ice salt bath to quench the reaction. The reaction solution was slowly added dropwise to 60 mL methanol to precipitate the polymer. The precipitate was separated by centrifugation (8500 rpm, 10 minutes) and then dissolved in 5 mL DMSO. This process was repeated 3 times to wash the polymer. Afterwards, the above polymer precipitate was dissolved in 5 mL DMSO, argon was introduced for deoxygenation for 20 minutes, and then 324 μL of n-butylamine was added under argon protection. The reaction lasted for 10 minutes. Similarly, the polymer was precipitated with methanol, dissolved with DMSO, and the polymer was washed three times. Finally, the polymer was dissolved in DMSO, dialyzed with ultrapure water for 3 days and freeze-dried (dialysis bag cutoff: 3.5 kDa) to obtain a yellow-white product, i.e., a UCST-type temperature-sensitive polymer P (AAm-co-AN). 1 H NMR (400 MHz, DMSO-d6): δ 7.71–6.94 (m, -NH2), 2.84–2.32 (m, polymer backbone, -CH-CONH2 and -CH-CN), 1.72–1.54 (m, polymer backbone, -CH2-).

[0098] e. Functionalization of gold nanorods: 0.15 mg mPEG-SH (Mw = 2000) was added to the SGNRs solution (2 mg / mL, 3 mL) prepared in step a, and ultrasonicated for 15 minutes to disperse evenly. 45 -b-PS 450Dissolved in 20mL N,N-dimethylformamide to make their final concentration 0.75mg / mL, slowly add SGNRs solution drop by drop to the above polymer mixed solution under continuous intense ultrasonic conditions, after ultrasonic reaction for 1h, continue stirring at 25℃ for 24 hours to complete ligand exchange. Then, centrifuge (1200r / min, 40min) to obtain surface functionalized gold nanorods USGNRs, wash with N,N-dimethylformamide and centrifuge twice to remove unmodified polymer (1200r / min, 30min). The prepared USGNRs were dispersed in tetrahydrofuran solution and stored at 4℃ (Au: 1mg / mL).

[0099] f1. Preparation of drug-loaded gold nanorod vesicles: Add the tetrahydrofuran solution of USGNRs prepared in d (Au: 1 mg / mL, 500 μL) to a 4 mL sample bottle, and slowly add 1 mL of 0.4 mM HEPES buffer (pH = 7.4) drop by drop under stirring conditions (500 r / min). After the addition is complete, place the reaction bottle in a 50°C oil bath and continue stirring for 10 minutes, then add 100 μL of 17-AAG tetrahydrofuran solution (1 mg / mL). After continuing to stir at 50°C for 10 minutes, cool the reaction solution to room temperature and stir it open for 24 hours to completely evaporate the solvent tetrahydrofuran. Finally, centrifuge (5000 r / min, 10 min) to obtain drug-loaded gold nanorod vesicles USGRV-17-AAG, wash with ultrapure water until there is no 17-AAG in the supernatant, and disperse the obtained USGRV-17-AAG in 1 mL ultrapure water for later use.

[0100] f2. Preparation of gold nanorod vesicles: Add the tetrahydrofuran solution of USGNRs prepared in step d (Au: 1 mg / mL, 500 μL) to a 4 mL sample bottle, and slowly add 1 mL of 0.4 mM HEPES buffer (pH = 7.4) drop by drop under stirring (500 r / min). After the addition is complete, stir the reaction bottle open at 25°C for 24 hours to completely evaporate the solvent tetrahydrofuran. Finally, centrifuge (5000 r / min, 10 min) to obtain gold nanorod vesicles USGRVs without drug loading, and disperse the obtained USGRVs in 1 mL of ultrapure water for use, and store at 4-6°C.

[0101] Transmission electron microscopy was used to analyze the morphology and particle size of the nanomaterials before and after modification and assembly. Figure 1As shown, the length of gold nanorods SGNRs is about 67.48±6.14nm, the width is about 8.82±1.15nm, and the aspect ratio is about 7.65 (a). The diameter of gold nanorod vesicles USGRVs formed by self-assembly of the modified gold nanorods is about 182.33±18.54nm (b). The diameter of gold nanorod drug-loaded vesicles USGRV-17-AAG loaded with chemotherapy drug 17-AAG is about 150.80±9.2nm (c).

[0102] The absorption spectra of the nanocarriers before and after modification and assembly were tested using a UV-visible spectrophotometer (UV-2600i with built-in integrating sphere module, Shimadzu). Figure 2 As shown, the longitudinal plasma absorption peak of gold nanorods SGNRs is located at 1083nm. After modification, the aspect ratio of the gold nanorods changes, resulting in a blue shift in the maximum absorption peak of USGNRs (1010nm); and after being assembled into nanorod vesicles, the absorption peak of USGRVs (1156nm) is red shifted due to the coupling effect between gold nanoparticles.

[0103] The Zeta potential of the nanocarriers before and after modification and assembly was measured using a laser particle size and Zeta potential meter. Figure 3 As shown in (a), due to the influence of CTAB, the gold nanorod surface ligand, the gold nanorod SGNRs are positively charged (10.3 mV). After surface functionalization, the USGNRs undergo charge reversal, and the polymer modification makes them negatively charged (-9.29 mV). After drug loading, the nanovesicle USGRV-17-AAG also has a negative charge (-20.6 mV).

[0104] The hydration kinetics particle size of the nanocarriers before and after modification and assembly was measured using a laser particle size and Zeta potential meter. The results are as follows: Figure 3 As shown in (b), the hydration kinetic particle sizes of USGRVs and USGRV-17-AAG are 190.1 nm and 169.5 nm, respectively.

[0105] The critical solution temperature of the prepared UCST polymer P(AAm-co-AN) was measured using a UV-visible spectrophotometer. Figure 4 As shown in (a), the critical solution temperature of UCST-type polymer P(AAm-co-AN) is 43°C.

[0106] The infrared spectrum of the prepared UCST polymer P(AAm-co-AN) was analyzed by Fourier transform infrared spectrometer. Figure 4 As shown in (b), the UCST polymer has a wavelength of 3196-3442 cm -1There is a broad vibration peak between 1669cm -1 There is a vibration peak of carbonyl (-C=O) in acrylamide at 2244cm -1 There is an obvious vibration peak of cyano group (-CN) in acrylonitrile at 2933cm -1 The above results prove that UCST polymer is composed of two monomers: acrylamide and acrylonitrile.

[0107] Example 2

[0108] Evaluation of the temperature-responsive drug release performance of USGRV-17-AAG, the specific steps are as follows:

[0109] The drug release of USGRV-17-AAG over time was detected at 37°C, 43°C and 50°C. Taking 37°C as an example, 1.2 mL of USGRV-17-AAG aqueous solution (100 μg / mL) was taken and stirred continuously in a 37°C water bath. 100 μL of the drug-loaded solution was taken out at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50 and 60 minutes respectively, and the filtrate was obtained by centrifugation with an ultrafiltration tube (10000 r / min, 5 min, 10 kDa). After diluting to 3 mL, its absorbance was detected at 332 nm, and the drug release amount was calculated based on the standard curve of 17-AAG in ultrapure water. Similarly, the temperature-responsive drug release performance evaluation of USGRV-17-AAG at 43°C and 50°C was studied. The research results are as follows Figure 5 shown.

[0110] Example 3

[0111] USGRV-17-AAG photothermal conversion performance test, the specific steps are as follows:

[0112] Irradiate the same concentration of USGRV-17-AAG solution with 1064 nm laser at different laser powers: 2 mL of 75 μg / mL USGRV-17-AAG aqueous solution was dispersed in a quartz cuvette and irradiated with 1064 nm laser at 0.33 W / cm 2 、0.69W / cm 2 , 1.00W / cm 2 and 1.33W / cm 2 The solution was irradiated with a power of 1000 W and the temperature change of the solution was monitored within 300 s using a thermocouple thermometer. Figure 6 (a) shown.

[0113] The same laser power of 1064nm laser was used to irradiate different concentrations of USGRV-17-AAG solutions: 2mL of 12.5μg / mL, 25μg / mL, 50μg / mL, 100μg / mL and 150μg / mL USGRV-17-AAG aqueous solutions were dispersed in a quartz cuvette. 2 The solution was irradiated with a power of 1000 W and the temperature change of the solution was monitored within 300 seconds using a thermocouple thermometer. Figure 6 (b) as shown.

[0114] Example 4

[0115] USGRV-17-AAG light and heat stability test, the specific steps are as follows:

[0116] 2 mL of USGRV-17-AAG aqueous solution (50 μg / mL) was placed in a quartz cuvette and irradiated with a 1064 nm laser (1 W / cm 2 ) Continuous irradiation for 5 minutes and then stop, record the temperature changes during the heating (5 minutes) and cooling (5 minutes) every 30 seconds, repeat the above process for 5 cycles, and the first cycle starts from room temperature (25℃). Figure 7 (a) shown.

[0117] Example 5

[0118] USGRV-17-AAG photothermal imaging test, the specific steps are as follows:

[0119] 1 mL of USGRV-17-AAG aqueous solution (100 μg / mL) was placed in a 1.5 mL centrifuge tube to test its photothermal heating efficiency. The laser power density was 1.33 W / cm 2 , using an infrared thermal imager to take photos at different times (0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 seconds). The research results are as follows Figure 7 (b) as shown.

[0120] Example 6

[0121] The specific steps for evaluating the performance of USGRV-17-AAG light-controlled release drug are as follows:

[0122] Continuous laser irradiation: 1 mL of USGRV-17-AAG aqueous solution (100 μg / mL) was placed in a quartz cuvette and irradiated with a power density of 1 W / cm 2The cuvette was continuously irradiated with a 1064nm laser, and 100μL of the solution was taken out at 2, 4, 6, 8, 10, 15, and 20 minutes, respectively. The filtrate was centrifuged (10000r / min, 5min, 10kDa), diluted to 3mL, and the drug release amount was calculated based on the 17-AAG standard curve in ultrapure water. The research results are as follows Figure 8 (a) shown.

[0123] Pulse laser irradiation: 1.2 mL of USGRV-17-AAG aqueous solution (100 μg / mL) was irradiated with 1064 nm laser at 1 W / cm at 0-2, 4-6, 8-10, 12-14, and 16-18 minutes. 2 The cuvette was irradiated with a power density of 100 μL and the laser was turned off at 2-4, 6-8, 10-12, 14-16, and 18-20 minutes. At the end of the irradiation, 100 μL of the solution was taken at 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 minutes, centrifuged (10,000 r / min, 5 minutes, 10 kDa), and the filtrate was diluted to 3 mL. The drug release amount was calculated based on the 17-AAG standard curve in ultrapure water. The research results are shown in Figure 8 (b) as shown.

[0124] Example 7

[0125] The specific steps of USGRV-17-AAG cytotoxicity evaluation are as follows:

[0126] MDA-MB-231 cells were cultured at 37°C (5% CO2) and cytotoxicity was detected using the cell counting kit-8 (CCK-8) assay. The cells were seeded in a 96-well plate, with 10,000 cells per well. After culturing for 24 hours, 100 μL of RPMI 1640 medium solution (10% FBS, 1% double antibody) of USGRV-17-AAG or USGRVs at concentrations of 0, 5, 10, 15, and 20 μg / mL was added.

[0127] No laser irradiation group: After culturing for 24 hours, the culture medium was replaced and 10 μL CCK-8 solution was added. After culturing for 1 hour, the absorbance of each well at 450 nm was detected and the survival rate of MDA-MB-231 cells at different concentrations was calculated.

[0128] Laser irradiation group: After adding USGRV-17-AAG or USGRVs solution, the cells were incubated for 4 hours and irradiated with 1064 nm laser at 1 W / cm 2 Each well was irradiated with a power density of 500 nm for 5 min, and after incubation for 20 h, the absorbance at 450 nm was measured and the cell survival rate was calculated.

[0129] The research results are as follows Fig. 9shown.

[0130] Example 8

[0131] USGRV-17-AAG live / dead cell staining evaluation, the specific steps are as follows:

[0132] MDA-MB-231 cells were seeded at a concentration of 80,000 cells / well in a 24-well plate and incubated at 37°C (5% CO2). After 24 hours, RPMI 1640 medium solution (10% FBS, 1% double antibody) containing PBS, 17-AAG (8.5 μM), USGRVs (40 μg / mL) and USGRV17-AAG (40 μg / mL) was added.

[0133] Laser irradiation group: After incubation for 4 hours, the laser irradiation group was irradiated at 1W / cm 2 After irradiation with 1064 nm laser for 5 minutes, the old medium was removed and the cells were washed with PBS after incubation for 20 hours. Live and dead cells were stained with Calcein-AM / propidium iodide (PI), respectively, and the cells were imaged using a fluorescent inverted microscope.

[0134] No laser irradiation group: The no laser irradiation group was incubated continuously, and the old culture medium was removed after 24 hours, and the cells were washed with PBS. Live cells and dead cells were stained with Calcein-AM / propidium iodide (PI), respectively, and the cells were imaged using a fluorescent inverted microscope.

[0135] The research results are as follows Fig.10 shown.

[0136] Example 9

[0137] The in vivo anti-tumor performance evaluation of USGRV-17-AAG is as follows:

[0138] In this study, 4-week-old healthy Balb / c female nude mice were injected into the right forelimb of each nude mouse with 100 μL of 0.5×10 7 When the tumor of mice implanted with MDA-MB-231 cancer cells grew to 100 mm 3The mice were randomly divided into 6 groups (n=5). Each group of mice was injected via tail vein: Group 1: saline (200 μL); Group 2: 17-AAG aqueous solution (17-AAG, 3 mg / kg, 100 μL); Group 3: USGRVs aqueous solution (50 mg / kg, 100 μL); Group 4: USGRVs aqueous solution (50 mg / kg, 100 μL); Group 5: USGRV-17-AAG aqueous solution (50 mg / kg, 100 μL); Group 6: USGRV-17-AAG aqueous solution (50 mg / kg, 100 μL). The injection was performed once every 3 days, and the treatment cycle was 15 days. Groups 4 and 6 were treated with 1064 nm laser (laser power density: 1 W / cm 2 , laser spot area: 1cm 2 , distance: 5 cm) to irradiate the tumor site of the mouse for 5 minutes.

[0139] Tumor volume and mouse weight were measured every 3 days, and photos of mice were taken on the 1st, 8th, and 15th days of treatment. After the treatment, the mice were dissected, and the heart, liver, spleen, lung, kidney and tumor tissues were taken, and blood was taken from the eyeball for routine blood tests. All organs were frozen and sections were made, and the tissues were stained with hematoxylin and eosin. Tumor sections were stained with terminal deoxynucleotidyl transferase (TdT) and 2"-deoxyuridine-5"-triphosphate (dUTP), and TUNEL terminal staining analysis was performed.

[0140] The research results are as follows Fig.11 shown.

Claims

1. A surface functionalized self-assembled gold nanorod, It is characterized in that The surface of the gold nanorod is modified with an upper critical solution temperature polymer and an amphiphilic polymer, wherein the critical solution temperature of the upper critical solution temperature polymer is 40-55°C.

2. The surface functionalized self-assembling gold nanorods according to claim 1, It is characterized in that The amphiphilic polymer has a structure shown in the following formula I: In Formula I, s is an integer between 40 and 50, and t is an integer between 440 and 460; and / or, The upper critical solution temperature polymer has a structure shown in the following formula II: In Formula II, m is an integer selected from 200-240, and n is an integer selected from 10-30.

3. The surface functionalized self-assembling gold nanorods as claimed in claim 1, It is characterized in that The gold nanorods have one or more of the following characteristics: The longitudinal length of the gold nanorods is 65-70 nm; The cross-sectional width of the gold nanorod is 8-9 nm; The aspect ratio of the gold nanorods is 7-8; The longitudinal plasmon absorption peak of the gold nanorod is located at 1000-1700 nm. Preferably, the longitudinal plasmon absorption peak of the gold nanorod is located at 1050-1150 nm.

4. A gold nanorod vesicle, It is characterized in that The gold nanorod vesicle is self-assembled from the surface-functionalized self-assembled gold nanorods described in any one of claims 1 to 3; preferably, the diameter of the gold nanorod vesicle is 180-185 nm; preferably, the longitudinal plasmon absorption peak of the gold nanorod vesicle is located at 1100-1200 nm.

5. A gold nanorod hybrid drug-loaded vesicle, It is characterized in that The gold nanorod hybrid drug-loaded vesicle comprises the gold nanorod vesicle as described in claim 4, and a drug in the inner cavity of the gold nanorod vesicle; preferably, the drug is an HSP90 inhibitor; preferably, the drug is tanspiramycin; preferably, the diameter of the gold nanorod hybrid drug-loaded vesicle is 145-155nm.

6. A method for preparing the gold nanorod hybrid drug-loaded vesicles according to claim 5, It is characterized in that The method comprises adding HEPES buffer to the solution of the surface functionalized self-assembled gold nanorods according to any one of claims 1 to 3, stirring, then adding a solution containing a drug, stirring, and evaporating the solvent to obtain the gold nanorod hybrid drug-loaded vesicles, wherein the solvent is preferably tetrahydrofuran.

7. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the gold nanorod hybrid drug-loaded vesicles according to claim 5 and a pharmaceutically acceptable carrier.

8. Use of the gold nanorod hybrid drug-loaded vesicles according to claim 5 in the preparation of a drug for treating tumors; preferably, the drug is used in combination with photothermal therapy.

9. Select from the following applications: Use of the gold nanorods described in any one of claims 1 to 3, the surface-functionalized self-assembled gold nanorods described in any one of claims 1 to 3, the amphiphilic polymer described in claim 1 or 2, and the upper critical solution temperature polymer described in claim 1 or 2 in the preparation of the gold nanorod hybrid drug-loaded vesicles described in claim 5; Use of the amphiphilic polymer described in claim 1 or 2 and the upper critical solution temperature polymer described in claim 1 or 2 in the preparation of the surface functionalized self-assembled gold nanorods described in any one of claims 1 to 3.

10. The method for light-controlled drug release of gold nanorod hybrid drug-loaded vesicles according to claim 5, It is characterized in that The method comprises irradiating the gold nanorod hybrid drug-loaded vesicles with a laser having a wavelength of 1060-1070 nm, wherein the power density of the laser is preferably 0.5-1.5 W / cm 2 .

Citation Information

Cited By

  • Gold nanorod composite Fmoc-L-tyrosine hydrogel as well as preparation method and application thereof

    CN121895599A